

Supplementary Table 1: Baseline characteristics of HIV/HBV coinfecting participants according to their HBsAg seroclearance status.

| Characteristics | Overall (<i>n</i> = 240) | HBsAg seroclearance (<i>n</i> = 27) | No HBsAg seroclearance (<i>n</i> = 213) | <i>t</i> / χ^2 | <i>P</i> -value |
|---|------------------------------|---|---|---------------------|-----------------|
| Male gender | 229 (95.4) | 26 (96.3) | 203 (95.3) | – | 1 |
| Age (years) | 41 (35–52) | 51 (40–56) | 40 (35–50) | 1947 | 0.006 |
| Ethnicity | | | | – | 1 |
| Han | 238 (99.2) | 27 (100) | 211 (99.1) | | |
| Others | 2 (0.8) | 0 | 2 (0.9) | | |
| HIV risk factor | | | | – | 0.026 |
| Homosexual | 149 (62.1) | 15 (55.6) | 134 (62.9) | | |
| Heterosexual | 61 (25.4) | 11 (40.7) | 50 (23.5) | | |
| IDU | 3 (1.2) | 1 (3.7) | 2 (0.9) | | |
| Other | 27 (11.2) | 0 | 27 (12.7) | | |
| Vertical transmission of HBV | | | | 5.941 | 0.015 |
| Yes | 59 (24.6) | 1 (3.7) | 58 (27.2) | | |
| No | 181 (75.4) | 26 (96.3) | 155 (72.8) | | |
| Baseline CD4 ⁺ T-cell (cells/ μ L) | 245 (109–361) | 266 (80–372) | 244 (116–358) | 3048 | 0.613 |

| | | | | | |
|-------------------------------|------------------------|-------------------------|------------------------|-------|-------|
| <200 | 99 (41.2) | 13 (48.1) | 86 (40.4) | – | 0.630 |
| 200–499 | 118 (49.2) | 11 (40.7) | 107 (50.2) | | |
| ≥500 | 23 (9.6) | 3 (11.1) | 20 (9.4) | | |
| HIV RNA (copies/mL) | 38,636 (12,975–91,333) | 50,100 (14,150–123,871) | 38,572 (12,200–90,494) | 2535 | 0.317 |
| Elevated baseline ALT* | | | | 0 | 0.990 |
| Yes | 58 (24.2) | 6 (22.2) | 52 (24.4) | | |
| No | 182 (75.8) | 21 (77.8) | 161 (75.6) | | |
| Duration of ART (years) | 5.4 (2.5–7.5) | 6.7 (5.3–7.9) | 5.1 (2.4–7.5) | 2062 | 0.017 |
| HBV DNA positive at baseline | 157 (65.4) | 16 (59.3) | 141 (66.2) | 0.249 | 0.618 |
| HBeAg positive at baseline | 99 (41.2) | 15 (55.6) | 84 (39.4) | 1.947 | 0.163 |
| Significant liver fibrosis† | 22 (9.2) | 5 (18.5) | 17 (8) | – | 0.083 |
| CD4 ⁺ T-cell gain‡ | 136 (73–215) | 179 (135–227) | 125 (66–213) | 1983 | 0.009 |

Data expressed as *n* (%) or median (IQRs).

*Defined as >50 U/L for men and >40 U/L for women.

†Based on FIB-4 score >3.25.

‡Defined as CD4⁺ T-cell count increase at 1 year after treatment.

–: Not applicable; ALT: Alanine aminotransferase; ART: Antiretroviral therapy; DNA: Deoxyribonucleic acid; FIB-4: Fibrosis 4; HBeAg: Hepatitis B e antigen;

HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HIV: Human immunodeficiency virus; IDU: Injection drug use; IQRs: Interquartile ranges; RNA: Ribonucleic acid.